While our “baseline” USC04 model (tumor cells lacking MGMT) is shown to respond to a single TMZ treatment and also benefits from adding TMZ to RT, the 2 MGMT-overexpressing models demonstrate no benefit. Here, MGMT is linked to neoplasm.